Insider Trading November 19, 2026 02:01 AM

Rhythm Pharmaceuticals Director Offloads $1.1 Million in Stock

Jean Christophe exercises options and sells 10,000 shares as RYTM trades near 52-week high

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
RYTM

Jean Christophe, a director at Rhythm Pharmaceuticals, sold 10,000 shares for $1,096,550 on November 17, 2026, with prices ranging from $106.81 to $115.00. The sale followed the exercise of 10,000 options at $34.89 each and was executed under a Rule 10b5-1 plan adopted on August 18, 2026. The transaction comes as RYTM shares trade at $119.04, near a 52-week high of $122.20, after a 36.5% six-month gain. The company recently reported third-quarter revenue of $92.1 million, beating consensus, but shares fell in premarket trading on spending and financing concerns.

Rhythm Pharmaceuticals Director Offloads $1.1 Million in Stock
RYTM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Director Jean Christophe sold 10,000 shares for $1,096,550 at prices between $106.81 and $115.00, following the exercise of options at $34.89 per share.
  • The sale was conducted under a Rule 10b5-1 trading plan adopted on August 18, 2026, and comes as RYTM trades near its 52-week high of $122.20.
  • Rhythm Pharmaceuticals reported third-quarter revenue of $92.1 million, beating consensus, but shares fell in premarket trading on spending and financing concerns.
  • Analyst actions were mixed: RBC maintained Outperform, Citizens raised its target to $166, and Oppenheimer reiterated Perform.

BOSTON - Jean Christophe, a director at Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), disposed of 10,000 shares of common stock on November 17, 2026, generating proceeds of $1,096,550, according to a regulatory filing. The shares were sold in multiple transactions at prices spanning $106.81 to $115.00 per share.

The sale was executed in three blocks: 5,000 shares at $106.81, 2,500 shares at $110.00, and 2,500 shares at $115.00. The transactions occurred as RYTM stock trades at $119.04, close to its 52-week high of $122.20, following a 36.5% gain over the past six months. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate, placing it among stocks on the Most Overvalued list.

Prior to the sales, Mr. Christophe acquired 10,000 shares of common stock through the exercise of stock options at $34.89 per share, totaling $348,900. These options had fully vested upon the earlier of one year from the grant date or the company’s next annual meeting of stockholders.

All reported transactions, including the option exercise and subsequent sales, were carried out pursuant to a Rule 10b5-1 trading plan. This plan was adopted by Mr. Christophe on August 18, 2026. Investors seeking deeper insights can access a comprehensive Pro Research Report on RYTM, one of over 1,400 US equities covered with expert analysis and actionable intelligence.

In other recent news, Rhythm Pharmaceuticals reported third-quarter 2026 results, exceeding Wall Street expectations with revenue of $92.1 million. This figure surpassed both the FactSet consensus of $85.6 million and Oppenheimer’s estimate of $81.8 million. The company also posted an adjusted loss of $0.61 per share, which was smaller than analysts’ projected loss of $0.71. RBC Capital maintained its Outperform rating on the stock, while Citizens raised its price target to $166, citing strong early performance of the Imcivree launch for hypothalamic obesity. The launch generated over 700 start forms from more than 500 prescribers in the two quarters following approval. Despite the positive earnings and revenue results, shares fell in premarket trading as investors considered the company’s spending plans and financing strategies. Oppenheimer reiterated a Perform rating on the stock following the earnings announcement. These developments highlight the ongoing interest and scrutiny from investors and analysts regarding Rhythm Pharmaceuticals’ financial performance and strategic direction.

Risks

  • Insider selling near a 52-week high could be perceived negatively by investors, potentially pressuring the stock price.
  • The company’s spending plans and financing strategies may continue to weigh on shares despite strong revenue growth.
  • Valuation concerns, as indicated by InvestingPro’s overvalued assessment, could lead to a price correction if growth expectations are not met.

More from Insider Trading

FRP Holdings Director John D. Baker II Increases Stake with $96,349 Purchase Nov 19, 2026 Astera Labs Accounting Chief Offloads $7,230 in Stock to Cover Taxes Nov 19, 2026 Cricut Accounting Chief Offloads $87,000 in Stock as Shares Hover Near 52-Week High Nov 19, 2026 VSE Corp CEO John Cuomo Offloads $338,964 in Stock Under Pre-Arranged Plan Nov 19, 2026 Morningstar's Mansueto Offloads $1.8 Million in Shares Near 52-Week High Nov 19, 2026